% | $
Quotes you view appear here for quick access.

Curis, Inc. Message Board

  • samsonisis samsonisis Oct 6, 2013 4:20 PM Flag

    New $CRIS Advisor - Lori Kunkel, M.D.

    Was CMO during the development and regulatory submissions of PCYC's ibrutinib, the wildy effective oral Bruton's tyrosine kinase (BTK) inhibitor. PCYC got FDA Breakthrough Status in early 2013 for ibrutinib. Dr. Kunkel was also CMO during development of what is now Onyx’s FDA approved Kyprolis – FDA approved for multiple myeloma. As of August 2013, now at $CRIS.

    Sentiment: Strong Buy

2.86+0.03(+1.06%)4:00 PMEDT